AUTORISATION D'ACCES PRECOCE REFUSEE à la spécialité ULTOMIRIS (ravulizumab) dans l'indication « traitement de la maladie du spectre de la neuromyélite optique chez les patients adultes présentant des anticorps anti-aquaporine 4 (AQP4) ».
See also
Décision d'accès précoce
03/08/2023
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
ap1er6p96XfYEsk2